The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-l, Interferon- , and Interferon- in the Serum of Patients with Septic Shock
Open accessAbstract
Serum concentrations of immunoreactive tumor necrosis factor/cachectin (TNF), interleukin-1 beta (IL-1 beta), interferon-gamma (IFN gamma), and interferon-alpha (IFN alpha) were prospectively measured in 70 patients with septic shock to determine their evolution and prognostic values. In a univariate analysis, levels of TNF (P = .002) and IL-1 beta (P = .05) were associated with the patient's outcome, but not IFN alpha (P = .15) and IFN gamma (P = .26). In contrast, in a stepwise logistic regression analysis, the severity of the underlying disease (P = .01), the age of the patient (P = .02), the documentation of infection (nonbacteremic infections vs. bacteremias, P = .03), the urine output (P = .04), and the arterial pH (P = .05) contributed more significantly to prediction of patient outcome than the serum levels of TNF (P = .07). After 10 days, the median concentration of TNF was undetectable (less than 100 pg/ml) in the survivors, whereas it remained elevated (305 pg/ml, P = .002) in the nonsurvivors. Thus, in patients with septic shock due to various gram-negative bacteria, other parameters than the absolute serum concentration of immunoreactive TNF contributed significantly to the prediction of outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BMDP Statistical Software 1981.
Bubolz, T. A., & Dixon, W. J. (1984) · Journal of the American Statistical Association · doi:10.2307/2288308 · Cited by 5,221
Shock and Tissue Injury Induced by Recombinant Human Cachectin
Tracey, K. J., Beutler, B., Lowry, S. F., Merryweather, J., Wolpe, S., Milsark, I. W., Hariri, R. J., Fahey, T. J., Zentella, A., Albert, J. D., et al. (1986) · Science · doi:10.1126/science.3764421 · Cited by 2,549
Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia
Tracey, K. J., Fong, Y., Hesse, D. G., Manogue, K. R., Lee, A. T., Kuo, G. C., Lowry, S. F., & Cerami, A. (1987) · Nature · doi:10.1038/330662a0 · Cited by 2,448 · cited 3×
“Tumor necrosis factor/cachectin (TNF) is a cytokine produced by activated macrophages [1] shown in experimental studies to be a primary mediator of the deleterious effects of endotoxin [2-10].”
BackgroundBeutler, B., Milsark, I. W., & Cerami, A. C. (1985) · Science · doi:10.1126/science.3895437 · Cited by 2,352
Detection of circulating tumor necrosis factor after endotoxin administration
Michie, H. R., Manogue, K. R., Spriggs, D. R., Revhaug, A., O'Dwyer, S., Dinarello, C. A., Cerami, A., Wolff, S. M., & Wilmore, D. W. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806093182301 · Cited by 1,677 · cited 4×
“levels in volunteers were undetectable 4 h after a single injection of endotoxin [8], 79 96 of our patients had detectable levels of TNF 10 h after the development of shock, probably r flecting differences of infectious stimuli between volunteers and patients.”
BackgroundInfluentialTumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.
Dinarello, C. A., Cannon, J. G., Wolff, S. M., Bernheim, H. A., Beutler, B., Cerami, A., Figari, I. S., Palladino, M. A., & O'Connor, J. V. (1986) · The Journal of experimental medicine · doi:10.1084/jem.163.6.1433 · Cited by 1,472
Cachectin: More Than a Tumor Necrosis Factor
Epstein, F. H., Beutler, B., & Cerami, A. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702123160705 · Cited by 1,432
Kreger, B. E., Craven, D. E., & McCabe, W. R. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90102-3 · Cited by 1,314
Waage, A., Brandtzaeg, P., Halstensen, A., Kierulf, P., & Espevik, T. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.1.333 · Cited by 1,173
The Cardiovascular Response of Normal Humans to the Administration of Endotoxin
Suffredini, A. F., Fromm, R. E., Parker, M. M., Brenner, M., Kovacs, J. A., Wesley, R. A., & Parrillo, J. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908033210503 · Cited by 1,102
Waage, A., Halstensen, A., & Espevik, T. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91728-4 · Cited by 1,096
Beutler, B., Mahoney, J., Le Trang, N., Pekala, P., & Cerami, A. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.5.984 · Cited by 821
Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo.
Beutler, B. A., Milsark, I. W., & Cerami, A. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.6.3972 · Cited by 763
Tumor Necrosis Factor and Interleuktn-1 in the Serum of Children with Severe Infectious Purpura
Girardin, E., Grau, G. E., Dayer, J.-M., Roux-Lombard, P., the J5 Study Group*, & Lambert, P.-H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198808183190703 · Cited by 737
Self-citationNatanson, C., Eichenholz, P. W., Danner, R. L., Eichacker, P. Q., Hoffman, W. D., Kuo, G. C., Banks, S. M., MacVittie, T. J., & Parrillo, J. E. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.3.823 · Cited by 568
RAISED SERUM LEVELS OF TUMOUR NECROSIS FACTOR IN PARASITIC INFECTIONS
Scuderi, P., Lam, K., Ryan, K., Petersen, E., Sterling, K., Finley, P., Ray, C. G., Slymen, D., & Salmon, S. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92007-6 · Cited by 458
New Concepts on the Pathogenesis of Fever
Dinarello, C. A., Cannon, J. G., & Wolff, S. M. (1988) · Clinical Infectious Diseases · doi:10.1093/clinids/10.1.168 · Cited by 367
Bryan, C. S., Reynolds, K. L., & Brenner, E. R. (1983) · Clinical Infectious Diseases · doi:10.1093/clinids/5.4.629 · Cited by 360
Plasma tumor necrosis factor and mortality in critically ill septic patients
DEBETS, J. M. H., KAMPMEIJER, R., P, M., BUURMAN, W. A., & VAN DER LINDEN, C. J. (1989) · Critical Care Medicine · doi:10.1097/00003246-198906000-00001 · Cited by 321
Calandra, T., Glauser, M. P., Schellekens, J., & Verhoef, J. (1988) · Journal of Infectious Diseases · doi:10.1093/infdis/158.2.312 · Cited by 263
Self-citationInterleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice.
Waage, A., & Espevik, T. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.6.1987 · Cited by 242
Waage, A., Espevik, T., & Lamvik, J. O. (1986) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.1986.tb02194.x · Cited by 129
Plasma Tumor Necrosis Factor Levels in Patients With Presumed Sepsis
Groote, M. A. D. (1989) · JAMA · doi:10.1001/jama.1989.03430020091035 · Cited by 76
Cited by
Pierrakos, C., & Vincent, J.-L. (2010) · Critical Care · doi:10.1186/cc8872 · Cited by 1,377
Bone, R. C. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-6-457 · Cited by 1,368
Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein
Fisher, C. J., Agosti, J. M., Opal, S. M., Lowry, S. F., Balk, R. A., Sadoff, J. C., Abraham, E., Schein, R. M. H., & Benjamin, E. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606273342603 · Cited by 1,241
Annane, D. (2000) · JAMA · doi:10.1001/jama.283.8.1038 · Cited by 1,000
Serum Cytokine Levels in Human Septic Shock
Pinsky, M. R., Vincent, J.-L., Deviere, J., Alegre, M., Kahn, R. J., & Dupont, E. (1993) · Chest · doi:10.1378/chest.103.2.565 · Cited by 884
Metadata
- Authors
- Calandra, T., Baumgartner, J.-D., Grau, G. E., Wu, M.-M., Lambert, P.-H., Schellekens, J., Verhoef, J., Glauser, M. P., & Swiss-Dutch J5 Immunoglobulin Study Group
- Venue
- Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1990-05-01
- Volume
- 161
- Issue
- 5
- Pages
- 982-987
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2321427723
- Cited by
- 547
- References
- 23
- FWCI
- 35.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.